Global Immunology Market worth $156,378.2 million : Qualiket Research

key market players in the Global Immunology Market are Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp., UCB SA, etc

Dallas, Texas, United states, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Global Immunology Market is estimated to be valued at US$ 91,850 Million in 2020 and is expected to reach USD 156,378.2 million by 2027, at a CAGR of 8% during the forecast period 2021–2027.

Immunology means a discipline of medical and biological investigation that studies the immune system. The immune system protects us against infection in a variety of ways. Diseases like autoimmunity, allergies, and cancer may occur when the human immune system is not functioning properly. Autoimmune diseases arises when the immune system attacks the body that it’s meant to protect.

Request a Sample to get extensive insights into the Immunology Market at:

Impact of the COVID-19 on Global Immunology Market

The global spread of COVID-19, during 2020 has led to widespread disruption of daily life, leading to lockdowns in attempts to mitigate the epidemic. Interruptions to healthcare systems and the management of chronic diseases has caused into patients having difficulty seeing HCPs and receiving treatment, including for autoimmune and inflammatory conditions, especially as several of these immunological disorders require continuing therapy. Immunological disorders whose treatment has been disturbed include psoriasis, rheumatoid arthritis, inflammatory bowel disease, and others.

Key Players

key market players in the Global Immunology Market are Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer, Novartis, Astellas, Alector, ImmuNext, Merck sharp & Dohme Corp., UCB SA, etc.

Key Development

May 2020 - AbbVie, Inc. announced the acquisition of Allergan Plc with an aim to expand its presence and strengthen its position in the pharmaceuticals sector across the globe.

In 2019, AbbVie received approval from the Food and Drug Administration (FDA) for the usage of ‘SKYRIZI’. The drug was aimed at the treatment of moderate to severe plaque psoriasis. This drug was inclined towards the treatment of adults diagnosed with psoriasis and have been recommended for or undergoing therapy.

Buy this Latest Study:

Market Segmentation

By Drug Class

  • Monoclonal antibody
  • Fusion Proteins
  • Immunosuppressant
  • Polyclonal antibody
  • Others

By Disease Indication

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Ankylosing Spondylitis
  • Inflammatory Bowel disease
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Regional Analysis

North America holds the highest contribution to the immunology market in terms of value due to high awareness and stringent measures towards diagnosis and immunization. Nevertheless, the growth of the market may be substantial in emerging economies in the Asia Pacific and Africa considering many incidence and prevalence rates for immunological disorders. Europe, Latin America also contributing to reducing order of value for the market.

To get the perfect launch ask for a custom report:

Have a Look at Related Report:

Global Gene Synthesis Market :

Global Laser Hair Removal Market:

Global Plastic Surgery Instruments Market:

Global Peptide Therapeutics Market:

About Us

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. 


Contact Data